Pr?diktion der Therapie der überaktiven Blase mittels katheterloser Langzeiturodynamik

详细信息    查看全文

• 作者：Prof. Dr. S. Wille (1)
  D. Tenholte (3)
  O.A. Cornely (2) (4)
  N. Muthen (1)
  U.-H. Engelmann (1)
  J. Mehner (3)
  O. Eminaga (1)
  J. Herden (1)
  P. Schumacher (2) (4)
  J. Paas (1)
  
• 关键词：Anticholinergika ; Detrusorüberaktivit?t ; Arzneimitteltherapie ; gezielte ; Harndrang ; imperativer ; Pollakisurie ; Anticholinergics ; Overactive detrusor ; Pharmaceutical treatment ; targeted ; Urinary urge incontinence ; Pollakiuria
• 刊名：Der Urologe A
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：53
• 期：12
• 页码：1812-1814
• 全文大小：364 KB
• 参考文献：1. Abrams P, Cardozo L, Fall M et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61:37-9 CrossRef
  2. Irwin DE, Milsom I, Kopp Z et al (2009) Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder. Eur Urol 56:14-0 CrossRef
  3. Klotz T, Bruggenjurgen B, Burkart M, Resch A (2007) The economic costs of overactive bladder in Germany. Eur Urol 51:1654-662 CrossRef
  4. Lucas MG, Bosch RJ, Burkhard FC et al (2012) EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol 62:1130-142 CrossRef
  5. Wagg A, Compion G, Fahey A, Siddiqui E (2012) Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 110:1767-774 CrossRef
  6. Avery K, Donovan J, Peters TJ et al (2004) ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn 23:322-30 CrossRef
  7. Cardozo L, Coyne KS, Versi E (2005) Validation of the urgency perception scale. BJU Int 95:591-96 CrossRef
  8. Paas J, Muthen N, Weiss V, Wille S (2014) Is the validated ICIQ-SF suitable for evaluation of OAB patients?: A data analysis of intravesicular botulinum toxin therapy. Urologe A 53:1518-522 CrossRef
  9. Thuroff JW, Abrams P, Andersson KE et al (2011) EAU guidelines on urinary incontinence. Actas Urol Esp 35:373-88 CrossRef
  10. Hashim H, Abrams P (2006) Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 175:191-94 CrossRef
  11. Digesu GA, Khullar V, Cardozo L, Salvatore S (2003) Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn 22:105-08 CrossRef
  12. Chu FM, Dmochowski R (2006) Pathophysiology of overactive bladder. Am J Med 119:3- CrossRef
  13. Wille S, Tenholte D, Engelmann U (2013) A system for long-term urodynamic studies without catheters. Eur Urol 63:966-68 CrossRef
  14. Wille S, Schumacher P, Paas J et al (2014) Catheterless long-term ambulatory urodynamic measurement using a novel three-device system. PLoS One 9:96280 CrossRef
  15. Tenholte D, Wille S, Hamacher J et al (2013) An Intravesical measurement system for catheterless long-term urodynamics. Biomed Tech (Berl). (Epub ahead of print). doi: 10.1515/bmt-2013-4223
  
• 作者单位：Prof. Dr. S. Wille (1)
  D. Tenholte (3)
  O.A. Cornely (2) (4)
  N. Muthen (1)
  U.-H. Engelmann (1)
  J. Mehner (3)
  O. Eminaga (1)
  J. Herden (1)
  P. Schumacher (2) (4)
  J. Paas (1)
  
  1. Klinik und Poliklinik für Urologie, Uniklinik K?ln, Kerpenerstr., 50931, K?ln, Deutschland
  3. Technische Universit?t Chemnitz, Chemnitz, Deutschland
  2. Zentrum für klinische Studien K?ln (ZKS K?ln), Uniklinik K?ln, K?ln, Deutschland
  4. Cologne Cluster of Excellence in Cellular Stress Responses in Aging-associated Diseases (CECAD), K?ln, Deutschland
  
• ISSN：1433-0563

文摘

In Germany, overactive bladder (OAB) syndrome affects around 6.5?million people over the age of 40. The primary treatment consists of anticholinergics or beta-3-receptor agonists. After an anticholinergic treatment period of around 4?months, compliance is around 40%, which is probably due a larger proportion of nonresponders. One condition of an efficient medication treatment is the presence of detrusor overactivity (DO). However, the detection rate of DO during standard urodynamics is very low. The primary goal in the future is to target OAB treatment by detection of DO. Using the Wille Capsule (WiCa) in an in vitro model, DO could be detected over a time period of 72?h, which would ensure a higher compliance to the OAB treatment in a positive way.